← All trials
NCT04309084
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 12, 2020
- Primary completion
- Mar 12, 2023
- Completion date
- Mar 12, 2023
- First posted
- Mar 16, 2020
- Last posted
- Mar 16, 2020
- Enrollment
- 108
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Celularity, Inc.Lead sponsor
Drugs studied
Indications studied
- Analgesics
- Antineoplastic Agents
- Blood Protein Disorders
- Cardiovascular Diseases
- Hematologic Diseases
- Hemorrhagic Disorders
- Immune System Diseases
- Immunoproliferative Disorders
- Lymphoproliferative Disorders
- Multiple Myeloma
- Neoplasms
- Neoplasms by Histologic Type
- Paraproteinemias
- Vascular Diseases
- Peripheral Nervous System Agents
- Sensory System Agents
- Analgesics, Non-Narcotic
- Hemostatic Disorders
- Physiological Effects of Drugs
- Neoplasms, Plasma Cell
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.